Safety and efficacy study of allogeneic human menstrual blood stem cells secretome to treat severe Covid-19 patients, clinical trial phase I&II

Iranian academic center for education culture and research0 个研究点目标入组 30 人开始时间: 待定最近更新: 2021年4月26日

适应症

试验速览

暂无简介。

•Aged 40-65 years
•Voluntarily participate in this clinical trial and sign off informed consent form
•Chest imaging confirm COVID-19 featured lesions in the lung
•The SARS-CoV-2 nucleic acid test was positive
•Diagnosed with severe pneumonia of COVID-19: respiratory distress, Respiratory rate (RR) = 30 times/min; resting oxygen saturation of 90% or less; arterial pressure of oxygen/the fraction of inspired oxygen= 300 mmHg; pulmonary imaging of focus within 24-48 hours > 50% progression

•History of drug reactions or allergies
•Pneumonia caused by bacteria, Mycoplasma, Chlamydia, Legionella, fungi, or other viruses
•Airway obstruction due to lung cancer or unknown factors
•Carcinoid syndrome
•History of epilepsy and long-term use of anticonvulsant drugs during the last 3 years
•History of long-term use of immunosuppressive drugs
•History of chronic respiratory illness that requires long-term oxygen therapy
•The patient is on blood or peritoneal dialysis
•Creatinine clearance <15 ml / min
•Moderate to severe liver disease (Child-Pugh score> 12)
•History of deep vein thrombosis (DVT) or pulmonary embolism over the past 3 years
•Being under ECMO or high-frequency oscillatory ventilation support
•Diagnostic of HIV, hepatitis B, and syphilis
•Pregnant or lactating women
•Lack of consciousness and inability to provide informed consent by the patient

发起方

Iranian academic center for education culture and research